Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS201618_0033 in uncomplicated Plasmodium falciparum malaria
PACTR202302515279954Phase 2Unknown
- Sponsor
- Merck KGaA
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2 trial of cabamiquine and pyronaridine in Malaria (2 arms), sponsored by Merck KGaA. Status: unknown.
02
Drugs
cabamiquinepyronaridine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202302515279954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202302515279954.